Article
Author: Garancini, Mattia ; Romano, Maurizio ; Giuliante, Felice ; Ercolani, Giorgio ; Ardito, Francesco ; Cillo, Umberto ; Boccia, Luigi ; Zanus, Giacomo ; Zanello, Matteo ; Di Gioia, Giulio ; Cescon, Matteo ; Torzilli, Guido ; Lai, Quirino ; La Barba, Giuliano ; Zimmitti, Giuseppe ; Maestri, Marcello ; Ruzzenente, Andrea ; Della Valle, Raffaele ; Crespi, Michele ; Conci, Simone ; Vivarelli, Marco ; Rossi, Massimo ; Aldrighetti, Luca ; Fumagalli, Luca ; Cipriani, Federica ; Cassese, Gianluca ; Jovine, Elio ; Germani, Paola ; Conticchio, Maria ; Molfino, Sarah ; Tarchi, Paola ; Ferrero, Alessandro ; Serenari, Matteo ; Grazi, Gian Luca ; Nicolini, Daniele ; Memeo, Riccardo ; Baiocchi, Gianluca ; Lauterio, Andrea ; Vitale, Alessandro ; Perri, Pasquale ; De Angelis, Michela ; Troci, Albert ; Romano, Fabrizio ; Fontana, Andrea Pierluigi ; De Carlis, Luciano ; Iaria, Maurizio ; Famularo, Simone ; Abu Hilal, Mohamed ; Izzo, Francesco ; I Troisi, Roberto ; Belli, Andrea ; Chiarelli, Marco ; C Giglio, Mariano
BACKGROUNDRecent papers report significant survival gain after liver resection in BCLC-B and -C HCC patients. The results of minimally invasive liver surgery (MILS) in such patients have not been widely investigated so far.METHODSData regarding patients undergoing MILS or open liver resection (OLR) for HCC staged BCLC -B and -C were extracted from the HERCOLES database. An inverse probability of treatment weighting (IPTW) method was adopted to balance the confounders. The primary outcome was a composite endpoint including post-hepatectomy liver failure, severe postoperative complications and in-hospital mortality.RESULTS627 patients were included (459 undergoing OLR and 168 receiving MILS). After IPTW, no difference was found in the composite endpoint between MILS and OLR (OR 0.86 [95%CI 0.46-1-60]; p = 0.62). MILS reduced the risk of receiving intra-operative transfusions (OR 0.28 [95%CI 0.13-0.58]; p < 0.001) and of developing postoperative ascites (OR 0.56 [95%CI 0,32-0,98]; p = 0.039), with reduced length of stay (OR 0.82 [95%CI 0.66-1.01]; p = 0.045). The survival analysis showed no differences between MILS and OLR for both OS (p = 0.13) and DFS (p = 0.491).CONCLUSIONMILS was shown to be safe and feasible for selected non-metastatic HCC patients staged BCLC B and C, reducing the risk of perioperative transfusions and postoperative ascites, and shortening the length of stay.